NASDAQ:GRTS Gritstone bio 5/11/2023 Earnings Report Profile Gritstone bio EPS ResultsActual EPS-$0.30Consensus EPS -$0.32Beat/MissBeat by +$0.02One Year Ago EPSN/AGritstone bio Revenue ResultsActual Revenue$2.44 millionExpected Revenue$4.00 millionBeat/MissMissed by -$1.56 millionYoY Revenue GrowthN/AGritstone bio Announcement DetailsQuarterDate5/11/2023TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesCompany Profile Gritstone bio Earnings HeadlinesGritstone Bio sets sale of assets through Bankruptcy CourtDecember 13, 2024 | bizjournals.comGritstone Oncology Inc (GRTSQ)November 27, 2024 | investing.comThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important updates you'll ever see. A new initiative, linked to President Trump's Executive Order #14196, has the potential to do more than just protect Social Security from collapse... According to renowned investor Louis Navellier, it could increase benefits by as much as 400%. | InvestorPlace (Ad)Gritstone bio, Inc. (GRTSQ)November 22, 2024 | finance.yahoo.comFirm Retention Summary: Gritstone bioNovember 20, 2024 | wsj.comGritstone’s bankruptcy filing reveals biotech’s tough choicesOctober 14, 2024 | bizjournals.comSee More Gritstone bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gritstone bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gritstone bio and other key companies, straight to your email. Email Address About Gritstone bioGritstone bio (NASDAQ:GRTS), a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.View Gritstone bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong Upcoming Earnings Interactive Brokers Group (7/17/2025)PepsiCo (7/17/2025)Cintas (7/17/2025)Netflix (7/17/2025)American Noble Gas (7/17/2025)U.S. Bancorp (7/17/2025)Novartis (7/17/2025)Abbott Laboratories (7/17/2025)Marsh & McLennan Companies (7/17/2025)Taiwan Semiconductor Manufacturing (7/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
